Chugai Pharmaceutical Co., Ltd. (4519.T)

JPY 6696.0

(-1.72%)

Market Cap (In JPY)

11018.37 Billion

Revenue (In JPY)

1111.36 Billion

Net Income (In JPY)

325.47 Billion

Avg. Volume

2.66 Million

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4572.0-7869.0
PE
-
EPS
-
Beta Value
0.497
ISIN
JP3519400000
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dr. Osamu Okuda
Employee Count
-
Website
https://www.chugai-pharm.co.jp
Ipo Date
2000-01-04
Details
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.